Company Overview


Innate Immunotherapeutics Limited (ASX: IIL) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Innate has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Innate Immunotherapeutics is a public company traded on the Australian Securities Exchange (ASX Code: IIL).